{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(2)"],"submitter":["van der Meer PB"],"pubmed_abstract":["<h4>Background</h4>This study aimed at investigating antiepileptic drug (AED) prescription preferences in patients with brain tumor-related epilepsy (BTRE) among the European neuro-oncology community, the considerations that play a role when initiating AED treatment, the organization of care, and practices with regard to AED withdrawal.<h4>Methods</h4>A digital survey containing 31 questions about prescription preferences of AEDs was set out among members of the European Association of Neuro-Oncology (EANO).<h4>Results</h4>A total of 198 respondents treating patients with BTRE participated of whom 179 completed the entire survey. Levetiracetam was the first choice in patients with BTRE for almost all respondents (90% [162/181]). Levetiracetam was considered the most effective AED in reduci"],"journal":["Neuro-oncology practice"],"pagination":["105-113"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8965049"],"repository":["biostudies-literature"],"pubmed_title":["Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members."],"pmcid":["PMC8965049"],"pubmed_authors":["Preusser M","Koekkoek JAF","van den Bent MJ","van der Meer PB","Dirven L","Taphoorn MJB","Ruda R"],"additional_accession":[]},"is_claimable":false,"name":"Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members.","description":"<h4>Background</h4>This study aimed at investigating antiepileptic drug (AED) prescription preferences in patients with brain tumor-related epilepsy (BTRE) among the European neuro-oncology community, the considerations that play a role when initiating AED treatment, the organization of care, and practices with regard to AED withdrawal.<h4>Methods</h4>A digital survey containing 31 questions about prescription preferences of AEDs was set out among members of the European Association of Neuro-Oncology (EANO).<h4>Results</h4>A total of 198 respondents treating patients with BTRE participated of whom 179 completed the entire survey. Levetiracetam was the first choice in patients with BTRE for almost all respondents (90% [162/181]). Levetiracetam was considered the most effective AED in reduci","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-04T07:33:33.959Z","creation":"2024-11-15T22:40:08.237Z"},"accession":"S-EPMC8965049","cross_references":{"pubmed":["35371521"],"doi":["10.1093/nop/npab059"]}}